<DOC>
	<DOC>NCT00073151</DOC>
	<brief_summary>The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with non-small cell lung cancer. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.</brief_summary>
	<brief_title>A Study of ABT-751 in Patients With Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<criteria>Inclusion Criteria Stage IIIB or IV nonsmall cell lung cancer. Recurrent tumor following treatment with paclitaxel or docetaxel. Able to tolerate normal activities of daily living. Adequate bone marrow, kidney and liver function. Exclusion Criteria Pregnant or breast feeding. Antitumor therapy within 4 weeks of the start of ABT751 administration. CNS metastasis.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>